Tech Transfer eNews Blog

KAHR licenses immunotherapy drug candidates from Thomas Jefferson U


By Jesse Schwartz
Published: April 7th, 2021

Cancer immunotherapy company KAHR has entered into a licensing agreement with Thomas Jefferson University (TJU) to advance multiple new drug candidates developed at the university.

The licensed candidates include fusion proteins DSP502 and DSP216, both designed to unleash the potential of innate and adaptive immune cells and to enhance anti-tumor immunoactivity through dual checkpoint inhibition.

“With this agreement we are adding a second fusion protein platform to our portfolio, enabling us to broaden our immuno-oncology target pipeline and positioning KAHR as a world leader in the fusion protein space,” says Yaron Pereg, CEO of KAHR. “These products are differentiated from current drug candidates targeting the same pathways as they target the ligands, not the receptors, thus increasing tumor selectivity by dual binding and avoiding potential redundancy compensation by other receptors of the same ligands.”

Mark Tykocinski, provost of TJU, comments, “Expanding our collaboration with the outstanding team at KAHR provides the opportunity to expand this new platform into novel targets and to unleash the activity of other immune cell types of the innate and adaptive immune systems.”

Heather Rose, the university’s Innovation Vice President, led the negotiations for the licensing agreement. “The synergy between Dr. Tykocinski’s innovative work on activation of anti-cancer immunity using multifunctional recombinant proteins and KAHR’s dedication to the development of cutting-edge immuno-recruitment cancer drugs is the next step to accelerate the translation of this technology to the clinic,” Rose says.

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment